EA201001596A1 - COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS - Google Patents

COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS

Info

Publication number
EA201001596A1
EA201001596A1 EA201001596A EA201001596A EA201001596A1 EA 201001596 A1 EA201001596 A1 EA 201001596A1 EA 201001596 A EA201001596 A EA 201001596A EA 201001596 A EA201001596 A EA 201001596A EA 201001596 A1 EA201001596 A1 EA 201001596A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
compositions
ros
proteinkinase inhibitors
proteinkinase
Prior art date
Application number
EA201001596A
Other languages
Russian (ru)
Other versions
EA018484B1 (en
Inventor
Тао Цзян
Пьерр-Ив Мишелли
Трук Нгок Нгуйен
Вэй Пэй
Баогэнь Ву
Сюфэн Чжу
Original Assignee
Айрм Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айрм Ллк filed Critical Айрм Ллк
Publication of EA201001596A1 publication Critical patent/EA201001596A1/en
Publication of EA018484B1 publication Critical patent/EA018484B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к новым производным триазина и пиримидина формул (1) или (2) и к способам применения таких соединений. Например, соединения по изобретению могут использоваться для лечения, облегчения или профилактики состояния, которое связано с ингибированием активности анапластической лимфомной киназы (ALK), онкогена c-ros (ROS), инсулиноподобного фактора роста (IGF-1R) и/или инсулинового рецептора (InsR) или их комбинации.The present invention relates to new derivatives of triazine and pyrimidine of the formulas (1) or (2) and to methods of using such compounds. For example, the compounds of the invention can be used to treat, alleviate or prevent a condition that is associated with inhibition of the activity of anaplastic lymphoma kinase (ALK), c-ros oncogen (ROS), insulin-like growth factor (IGF-1R) and / or insulin receptor (InsR ) or combinations thereof.

EA201001596A 2008-04-07 2009-04-03 Compounds and compositions as kinase inhibitors EA018484B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4311108P 2008-04-07 2008-04-07
US9588308P 2008-09-10 2008-09-10
PCT/US2009/039380 WO2009126514A1 (en) 2008-04-07 2009-04-03 Compounds and compositions as kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201001596A1 true EA201001596A1 (en) 2011-04-29
EA018484B1 EA018484B1 (en) 2013-08-30

Family

ID=40786670

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001596A EA018484B1 (en) 2008-04-07 2009-04-03 Compounds and compositions as kinase inhibitors

Country Status (13)

Country Link
US (1) US8518931B2 (en)
EP (1) EP2271645A1 (en)
JP (1) JP5214799B2 (en)
KR (1) KR20110002080A (en)
CN (1) CN102056925A (en)
AR (1) AR071300A1 (en)
AU (1) AU2009233963B2 (en)
BR (1) BRPI0910979A2 (en)
CA (1) CA2720944C (en)
EA (1) EA018484B1 (en)
MX (1) MX2010011069A (en)
UY (1) UY31750A (en)
WO (1) WO2009126514A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI389893B (en) 2007-07-06 2013-03-21 Astellas Pharma Inc Di (arylamino) ary1 compound
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
SI2300013T1 (en) 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
MX2011011875A (en) 2009-05-08 2011-12-08 Astellas Pharma Inc Diamino heterocyclic carboxamide compound.
WO2012097478A1 (en) * 2011-01-21 2012-07-26 Abbott Laboratories Bicyclic carboxamide inhibitors of kinases
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
SG11201408816QA (en) 2012-07-03 2015-03-30 Aurigene Discovery Tech Ltd 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
AU2013344049B2 (en) * 2012-11-06 2017-12-21 Fochon Pharmaceuticals, Ltd. ALK kinase inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN103570728B (en) * 2013-11-12 2015-12-30 山东大学 Also [1,5-a] pyridine derivatives and preparation method thereof and the application of a kind of substituted pyrazolecarboxylic
ES2715676T3 (en) * 2014-03-27 2019-06-05 Janssen Pharmaceutica Nv Substituted 4,5,6,7-tetrahydro-pyrazolo [1,5-a] pyrazine derivatives and 5,6,7,8-tetrahydro-4h-pyrazolo [1,5-a] [1,4] diazepine as ros1 inhibitors
WO2016130920A2 (en) * 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Lrrk2 inhibitors and methods of making and using the same
US11046698B2 (en) 2017-07-28 2021-06-29 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
CN110483526B (en) * 2019-09-09 2021-10-01 辽宁大学 Pyrazolo [1,5-a ] pyrimidine derivative containing aryl hydrazone structure and application thereof
GB201915618D0 (en) 2019-10-28 2019-12-11 Univ Oslo ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7406641A (en) 1973-05-22 1974-11-26
JP2004516297A (en) 2000-12-20 2004-06-03 ソシエテ・ド・コンセイユ・ド・ルシエルシエ・エ・ダアツプリカーション・シヤンテイフイツク・（エス．セー．エール．アー．エス） Inhibitors of cyclin dependent kinase (CDK) and glycogen synthase kinase-3 (GSK-3)
FR2842809A1 (en) * 2002-07-26 2004-01-30 Greenpharma Sas NOVEL SUBSTITUTED PYRAZOLO [1,5-a] -1,3,5-TRIAZINES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, USE AS A MEDICAMENT AND METHODS FOR THEIR PREPARATION
EP1534712B1 (en) * 2002-09-04 2007-05-16 Schering Corporation Pyrazolo[1,5-a]pyrimidine compounds as cyclin dependent kinase inhibitors
EP1599482A4 (en) * 2003-02-28 2008-10-01 Teijin Pharma Ltd Pyrazolo 1,5-a pyrimidine derivatives
GB0305559D0 (en) * 2003-03-11 2003-04-16 Teijin Ltd Compounds
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2005035516A1 (en) * 2003-10-10 2005-04-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
AR047969A1 (en) * 2004-02-25 2006-03-15 Schering Corp PIRAZOLOTRIAZINAS AS QUINASA INHIBITORS
JP2006160628A (en) 2004-12-03 2006-06-22 Ishihara Sangyo Kaisha Ltd COMPOSITION FOR TREATING OR PREVENTING DISEASE REQUIRING ADMINISTRATION OF ADENOSINE A2a RECEPTOR AGONIST
US7741318B2 (en) * 2004-12-21 2010-06-22 Schering Corporation Pyrazolo [1,5-A]pyrimidine adenosine A2a receptor antagonists
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof

Also Published As

Publication number Publication date
AR071300A1 (en) 2010-06-09
US8518931B2 (en) 2013-08-27
CA2720944A1 (en) 2009-10-15
UY31750A (en) 2009-12-14
US20110190264A1 (en) 2011-08-04
EP2271645A1 (en) 2011-01-12
AU2009233963B2 (en) 2011-10-06
KR20110002080A (en) 2011-01-06
JP2011516554A (en) 2011-05-26
CN102056925A (en) 2011-05-11
JP5214799B2 (en) 2013-06-19
WO2009126514A1 (en) 2009-10-15
MX2010011069A (en) 2010-11-12
BRPI0910979A2 (en) 2016-01-05
AU2009233963A1 (en) 2009-10-15
CA2720944C (en) 2012-12-18
EA018484B1 (en) 2013-08-30
WO2009126514A8 (en) 2010-10-21

Similar Documents

Publication Publication Date Title
EA201001596A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
EA201001597A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
EA201100077A1 (en) DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS
MX2010002336A (en) Compounds and compositions as kinase inhibitors.
EA201100078A1 (en) DERIVATIVES OF PYRIMIDINE AS KINASE INHIBITORS
EA200970557A1 (en) COMPOUNDS AND COMPOSITIONS AS PROTEINKINASE INHIBITORS
UA100846C2 (en) Compounds and compositions as protein kinase inhibitors
TW200716118A (en) Aminopyrimidines as kinase modulators
TW200718693A (en) Aminopyrimidines as kinase modulators
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
MX2010009207A (en) Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors.
MY153727A (en) Pyridazinone derivatives
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
PH12014501355A1 (en) Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
TW200716598A (en) Aminoquinoline and aminoquinazoline kinase modulators
EA201100580A1 (en) IMIDAZOPIRIDAZINCARBONITRILE USED AS KINASE INHIBITORS
MX2012013197A (en) Indazole inhibitors of kinase.
MX2009011950A (en) Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors.
TW200716599A (en) Alkylquinoline and alkylquinazoline kinase modulators
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2011007165A (en) Pyridazinone derivatives.
MX2009012079A (en) Condensed heterocyclic compounds as inhibitors of protein kinases.
MX2010002096A (en) Thiadiazinone derivatives.
MX2011007209A (en) Pyridazinone derivatives.
CU23952B1 (en) PIRIMIDINE DERIVATIVES AS QUINASA INHIBITORS

Legal Events

Date Code Title Description
MC4A Revocation of a eurasian patent under opposition procedure

Designated state(s): AM AZ BY KZ KG MD TJ TM RU